Legal Analysis of the Legal Protection of Patients Participating in New Drug Clinical Trials
The Medical Journal of Hospital Management and Health Law · 01.01.2026 · 2 (2)
DOI: 10.70070/9xm5a589 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Journal of Hospital Management and Health Law, online erschienen am 01.01.2026. Verfasst von E.Nasution und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
The rapid development of pharmaceutical biotechnology necessitates clinical trials on human subjects to ensure drug safety and efficacy, yet this process inherently exposes patient-participants to severe health risks and potential exploitation. This study examines the adequacy of current legal frameworks in safeguarding human subjects during clinical trials of new investigational drugs.
Methods
This study employs a normative juridical research method, analyzing primary, secondary, and tertiary legal materials, including international guidelines, national healthcare statutes, and consumer protection regulations.
Results
The analysis reveals that while basic regulatory frameworks exist, significant legal vacuums remain regarding strict liability for clinical trial injuries, the enforceability of informed consent under asymmetric medical relationships, and comprehensive institutional oversight mechanisms.
Discussion
The discussion comprehensively integrates a literature review regarding patient autonomy, bioethics, and state responsibility, highlighting how the unequal bargaining power between pharmaceutical sponsors and vulnerable patients undermines genuine consent. It evaluates the legal nature of clinical trial agreements, identifying them as adhesion contracts that require intervention through mandatory indemnification clauses and enhanced Institutional Review Board oversight.
Conclusions
Current legal protections are fragmented and insufficient to address the complexities of modern clinical trials, necessitating a shift toward robust statutory strict liability and standardized operational protocols. It is recommended that the legislature enact a dedicated statute governing clinical trials and that healthcare authorities establish a mandatory state-backed insurance scheme to provide immediate compensation for injured participants without the burden of proving negligence.
Zitieren
APA
E.Nasution, & F.Alamsyah (2026). Legal Analysis of the Legal Protection of Patients Participating in New Drug Clinical Trials. The Medical Journal of Hospital Management and Health Law, 2(2). https://doi.org/10.70070/9xm5a589
Vancouver
E.Nasution, F.Alamsyah. Legal Analysis of the Legal Protection of Patients Participating in New Drug Clinical Trials. The Medical Journal of Hospital Management and Health Law. 2026;2(2). doi:10.70070/9xm5a589
BibTeX
@article{ENasution2026,
author = {E.Nasution and F.Alamsyah},
title = {Legal Analysis of the Legal Protection of Patients Participating in New Drug Clinical Trials},
journal = {The Medical Journal of Hospital Management and Health Law},
year = {2026},
volume = {2},
number = {2},
doi = {10.70070/9xm5a589}
}
EUVIMED